Safety and Efficacy of Excimer Laser Atherectomy Combined with a Drug-Coated Balloon in De Novo Femoral Popliteal Artery Disease: A Retrospective Study
Annals of Vascular Surgery · 2024
DOI: 10.1016/j.avsg.2023.09.072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Vascular Surgery, 2024. Verfasst von Dikang Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Angioplasty, Balloon. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
BACKGROUND: The effectiveness of excimer laser atherectomy (ELA) combined with drug-coated balloon (DCB) for de novo femoropopliteal artery disease (FPAD) is currently unknown. This case series evaluated the clinical outcomes of ELA combined with DCB in de novo FPAD from a real-world clinical perspective. METHODS: We conducted a retrospective study of patients treated with ELA + DCB for de novo FPAD between November 2016 and January 2020. The primary efficacy endpoint was the initial patency rate; secondary endpoints included target lesion revascularization without clinically driven target lesion revascularization (CD-TLR) and technical success. Primary safety endpoints included all-cause death, unplanned major amputation, and postoperative complications. RESULTS: The mean follow-up was 37.8 ± 25.3 months and included 56 consecutive patients (68.23 ± 8.01 years, 41 men). Forty-three patients had lifestyle-restricted claudication, and 13 patients had critical limb-threatening ischemia. The mean length of the lesion was 178.41 mm in all patients. The total lesion occlusion rate was 48.2 (n = 27), and the overall technical success rate was 100%. The 12-month, 24-month, 36-month, and 48-month primary patency rates of the ELA + DCB group were 75%, 66.1%, 58.9%, and 42.8%, respectively. Freedom from CD-TLR at 12, 24, 36, and 48 months was 83.9%, 80.3%, 76.8%, and 57.1%, respectively. CONCLUSIONS: In real-world clinical practice, ELA + DCB appears to be a safe and effective endovascular treatment for de novo FPAD, with a low rate of freedom from CD-TLR and a good patency rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Electronic address: gu15901598209@aliyun.com.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Pan, D., Guo, J., Su, Z., Meng, W., Wang, C., Guo, J., & Gu, Y. (2024). Safety and Efficacy of Excimer Laser Atherectomy Combined with a Drug-Coated Balloon in De Novo Femoral Popliteal Artery Disease: A Retrospective Study. Annals of Vascular Surgery. https://doi.org/10.1016/j.avsg.2023.09.072
Vancouver
Pan D, Guo J, Su Z, Meng W, Wang C, Guo J, et al. Safety and Efficacy of Excimer Laser Atherectomy Combined with a Drug-Coated Balloon in De Novo Femoral Popliteal Artery Disease: A Retrospective Study. Annals of Vascular Surgery. 2024. doi:10.1016/j.avsg.2023.09.072
BibTeX
@article{Pan2024,
author = {Pan, Dikang and Guo, Julong and Su, Zhixiang and Meng, Wenzhuo and Wang, Cong and Guo, Jianming and Gu, Yongquan},
title = {Safety and Efficacy of Excimer Laser Atherectomy Combined with a Drug-Coated Balloon in De Novo Femoral Popliteal Artery Disease: A Retrospective Study},
journal = {Annals of Vascular Surgery},
year = {2024},
doi = {10.1016/j.avsg.2023.09.072}
}
EUVIMED